A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.
- Who can join
- Adults 18 to 68, have alcohol use disorder, BMI 18+.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 5 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Alcohol Use Disorder (AUD). Also studied in: Obesity (BMI Equal to or >30).
Full scientific study title: Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes.
Who can join
Adults 18 to 68, have alcohol use disorder, BMI 18+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Male and females ages 18-60 and BMI in 30-49.9 kg/m2;
- regular weekly alcohol use (at least 3X/week) prior to admission;
- must meet current DSM-V criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-V;
- Good health as verified by screening and physical examination;
- Able to read English and complete study evaluation;
Key exclusion criteria
- Meet current criteria for moderate to severe substance use disorders from abuse of any another psychoactive substance, excluding nicotine;
- Current use of opiates;
- Current use of psychiatric medications, including benzodiazepine-based sedatives/anxiolytics and anticonvulsants, non SSRI antidepressants, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), acamprosate, naltrexone, antabuse, baclofen, varenicline;
- Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania);
- Endocrine or immune disorders, including diagnosis of diabetes (T2D or T1D) by American Diabetes Association (ADA) criteria or a history of HgbA1c \>6.5% and on current medications for T2D treatment;
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
Connecticut1 site
- Yale Stress CenterNew Haven, Connecticut
Timeline
Scheduled start: October 1, 2026. Expected completion: October 31, 2031. Last updated on ClinicalTrials.gov: August 19, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
